REGISTER
After China's NRDL Win, Innovative Drugs Still Face the "Last Mile" Into Hospitals
About 80% of China's newly approved innovative drugs now reach the national reimbursement drug list within two years, yet a third-party analysis finds median hospital coverage sits near 5% a year after negotiations. A case study of **Innovent Biologics, Inc.** shows how pricing pressure, pharmacy-committee bottlenecks and outdated procurement incentives can stall access even after reimbursement approval.

SHANGHAI — Roughly 80% of China's newly approved innovative drugs now enter the National Reimbursement Drug List (NRDL) within two years of launch, a pace that has reshaped pharmaceutical strategy in the country. A new wave of industry reporting, however, suggests that reimbursement is only the starting line. According to an IQVIA 2025 study cited by Chinese trade outlet Yaochuangxin, the median coverage rate of 2024-batch negotiated drugs across China's tertiary hospitals was approximately 5% one year after listing.

The gap reflects structural friction at what Chinese industry players call the "last mile" — the path from national reimbursement to hospital pharmacy shelves and, ultimately, to a physician's prescription pad.

The Challenge Beyond the Reimbursement List

Drug procurement in China operates through hospital-level pharmacy and therapeutics committees, commonly referred to as Yao Shi Hui. Industry interviews highlighted three persistent bottlenecks:

·Infrequent meetings. Many hospitals convene such committees only once or twice a year, and new-drug entry is not always on the agenda.

·Strict quotas. Tertiary comprehensive hospitals are generally capped at about 1,500 drug types, and leading academic centers often apply additional limits per supplier. Adding a new drug typically requires removing an existing product.

·Backlogs. Some hospitals have not held a new-drug-focused committee in five or six years, leaving hundreds of negotiated products queued.

China's National Healthcare Security Administration has called on hospitals to convene committees "in a timely manner," and several provinces — including Guangdong, Fujian, Beijing and Sichuan — now require quarterly meetings. The drug zero-markup policy, which removed the historical profit margin on pharmaceuticals, has also shifted inpatient drugs from a revenue line to a cost center, reducing hospitals' financial incentive to adopt high-cost innovative therapies.

Case Study: Innovent Biologics, Inc.

Founded in 2011 in Suzhou Industrial Park by returnee scientist Dr. Dechao Yu, **Innovent Biologics, Inc.** has grown to roughly 9,000 employees and, per company disclosures, ranks among the world's top 30 pharmaceutical companies by market capitalization. The firm has brought 19 to 20 products to market and is developing 39 candidates, with manufacturing capacity of 140,000 liters and a global pipeline involving partners such as Eli Lilly, Roche, Sanofi, Takeda and Pfizer.

Yu has said the company aims to become a world-class biopharmaceutical firm by 2030.

Three products illustrate both the company's commercial reach and the access pressures it faces.

Sintilimab Injection (PD-1 Inhibitor)

Approved in December 2018, sintilimab was priced at 7,838 RMB per dose at launch. After entering the NRDL in 2019, the price fell 64% to 2,843 RMB; subsequent renewal brought it to 1,080 RMB, described by the company as the lowest list price among PD-1 inhibitors in the directory. Reported annual treatment cost stands at approximately 30,000-40,000 RMB, roughly 1/30 of the U.S. equivalent for PD-1 inhibitors in the same class. After reimbursement, out-of-pocket costs for patients can fall to about 10,000 RMB or less, depending on region.

In a reported single-arm analysis in relapsed or refractory classical Hodgkin lymphoma, approximately 98% of patients achieved disease control, around 85% saw tumor size reduced by more than half, and roughly 45% achieved complete radiographic response on imaging. Sales climbed from about 1 billion RMB in the first full year on the market to 4.2 billion RMB in 2025, and the product has reportedly been used by more than 3.5 million patients.

Tafolecimab Injection (PCSK9 Inhibitor)

Listed in the NRDL in 2024 with a price of 286 RMB per dose, tafolecimab allows dosing intervals as long as six weeks. Annual treatment cost is reported at a few thousand RMB before insurance.

Teprotumumab N01 Injection for Thyroid Eye Disease

Approved in March 2025 for thyroid eye disease (TED) — a condition for which no disease-specific biologic therapy had previously been approved in China — the product entered the NRDL by the end of 2025. The price reportedly dropped about 60% to around 6,000 RMB per dose after reimbursement, putting annual treatment cost at about 1/15 of the comparable U.S. product, according to company statements. Patient support programs and reimbursement can further reduce out-of-pocket expenses.

Global Partnerships

Innovent Biologics, Inc.'s outbound licensing activity has accelerated. The company's 2015 deal with Eli Lilly was reported at 456 million USD total with 56 million USD upfront. In October 2025, Takeda signed an agreement with 1.2 billion USD upfront and up to 11.4 billion USD total, covering IBI363 (PD-1/IL-2α bispecific), IBI343 (CLDN18.2 ADC) and IBI3001 (EGFR/B7-H3 ADC). In May 2026, a separate arrangement with Pfizer was reported at 650 million USD upfront and up to 10.5 billion USD total.

Several agreements use a co-development, co-commercialization model in which **Innovent Biologics, Inc.** participates in global clinical and commercial strategy and shares in downstream economics. According to the company, five pipeline assets are in global pivotal trials, including three in or entering global Phase III studies.

Editorial Perspective

Trade publication reporting, including the Yaochuangxin series that produced the underlying source material, frames reimbursement as the beginning of the commercial journey rather than its conclusion. Several executives quoted in the original coverage emphasized that without sustainable pricing and predictable hospital access, the cycle from innovation to reinvestment becomes harder to maintain.

Limitations and Caveats

The figures cited above come from a sponsored industry visit and from company-reported disclosures. Coverage statistics, patient counts and pricing details should be read as company-reported unless independently verified. Clinical efficacy data for sintilimab in Hodgkin lymphoma come from a single-arm trial and cannot be directly compared with standard-of-care outcomes. Pricing comparisons with U.S. products reflect list prices and do not adjust for insurance rebates, net pricing or indication-specific dosing differences.

Outlook

Industry stakeholders interviewed for the underlying series suggest that quarterly committee cycles, hospital-level economic reform and clearer "green channel" pathways for breakthrough products could narrow the access gap. Whether such measures translate into measurably higher NRDL uptake in 2026 and beyond remains to be seen.

0
0
Loading